4747.Two

4747.TWO maintains a strong liquidity position, with a current ratio of 3.79 and cash and equivalents of TWD 567 million, which is well above the industry median. The company's liquidity_fpt score of 0.85 indicates a robust ability to meet short-term obligations without reliance on external financing.

Profitability metrics show a return on equity (ROE) of 3.13% and a return on assets (ROA) of 2.56%, both below the industry median for pharmaceutical firms. The company's operating margin of 12.87% is also below the median, indicating room for improvement in cost control and pricing power.

The company's revenue is concentrated in a few therapeutic areas, with oncology and rare diseases accounting for over 70% of total revenue. Geographically, the majority of revenue is derived from the Asia-Pacific region, with a smaller portion from North America and Europe.

Growth trajectory is modest, with a projected revenue increase of 2.1% in the current fiscal year and 3.4% in the next fiscal year. This aligns with the broader industry trend of moderate growth driven by new product launches and regulatory approvals.

Risk factors include a low liquidity risk and a low dilution potential, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.15 is well below the industry median, and there are no near-term pressures for equity issuance.

Recent events include the approval of a new oncology drug in the second quarter of 2024, which is expected to contribute to revenue growth in the coming years. The company also announced a partnership with a biotech firm to co-develop a pipeline candidate in the rare disease space.